
  
    
      
        Background_NNP
        Loss_NN of_IN Fhit_NNP protein_NN is_VBZ among_IN the_DT earliest_RBS known_VBN events_NNS
        in_IN the_DT development_NN of_IN a_DT variety_NN of_IN the_DT most_RBS common_JJ and_CC
        lethal_JJ human_JJ malignancies_NNS [_NN 1_CD ]_NN ._. Loss_NN of_IN Fhit_NNP leads_VBZ to_TO
        cells_NNS that_WDT are_VBP deficient_NN in_IN programmed_VBN cell_NN death_NN and_CC that_IN
        form_NN tumors_NNS in_IN mice_NNS while_IN Fhit_NNP reexpression_NN in_IN Fhit-cancer_NNP
        cells_NNS reduces_VBZ tumorigenicity_NN and_CC restores_NNS programmed_VBN cell_NN
        death_NN [_NN 2_CD 3_CD 4_CD 5_CD 6_CD ]_NN ._. Infection_NNP of_IN 
        Fhit_NNP +_NN /_NN -_: mice_NNS with_IN viruses_NNS that_IN
        re-express_JJ Fhit_NNP reduce_VB cancer_NN occurrence_NN [_NN 7_CD ]_NN ,_, apparently_RB
        by_IN killing_VBG pre-neoplastic_JJ cells_NNS that_WDT have_VBP lost_VBN the_DT
        wild-type_JJ 
        Fhit_NNP allele_NN ._. Human_NNP Fhit_NNP protein_NN ,_, a_DT
        member_NN of_IN the_DT Fhit_NNP branch_NN of_IN the_DT histidine_NN triad_NN
        superfamily_RB of_IN nucleotide-binding_JJ proteins_NNS ,_, binds_NNS and_CC
        hydrolyzes_NNS diadenosine_NN polyphosphates_NNS such_JJ as_IN ApppA_NNP and_CC
        AppppA_NNP (_( 
        1_LS )_) into_IN AMP_NNP plus_CC ADP_NNP and_CC ATP_NNP ,_,
        respectively_RB [_NN 8_CD 9_CD 10_CD ]_NN ._. His_PRP$ 96_CD ,_, which_WDT is_VBZ responsible_JJ for_IN
        covalent_NN catalysis_NNS and_CC more_JJR than_IN 4_CD ×_NN 10_CD 6_CD -_: fold_VB of_IN rate_NN
        enhancement_NN in_IN ApppA_NNP hydrolysis_NNS [_NN 9_CD 11_CD 12_CD 13_CD ]_NN ,_, is_VBZ
        nonetheless_RB dispensable_JJ for_IN ApppA-binding_NNP and_CC tumor_NN
        suppression_NN ,_, suggesting_VBG that_IN Fhit_NNP function_NN in_IN tumor_NN
        suppression_NN depends_VBZ on_IN formation_NN of_IN an_DT E-S_NNP complex_JJ [_NN 2_CD 12_CD ]_NN
        ._. If_IN Fhit-substrate_NNP complexes_NNS promote_VBP tumor_NN suppression_NN by_IN
        stimulating_VBG a_DT pro-apoptotic_JJ effector_NN ,_, then_RB Fhit_NNP inhibitors_NNS
        that_WDT resemble_VBP natural_JJ substrates_NNS may_MD promote_VB Fhit_NNP function_NN ._.
        Similarly_RB ,_, Fhit_NNP inhibitors_NNS with_IN normative_JJ features_NNS may_MD
        antagonize_VB Fhit_NNP function_NN ._. Either_CC class_NN of_IN compounds_NNS may_MD be_VB
        important_JJ in_IN dissecting_VBG Fhit_NNP cell_NN biology_NN and_CC regulating_VBG
        apoptosis_NNS ._.
        Making_VBG use_NN of_IN a_DT synthesis_NN strategy_NN to_TO link_VB adenosine_NN 5_CD '_'' -_:
        
        O_NNP -_: phosphates_NNS and_CC phosphorothioates_NNS
        to_TO short-chain_JJ polyols_NNS [_NN 14_CD ]_NN ,_, we_PRP evaluate_VBP four_CD inhibitor_NN
        parameters_NNS and_CC obtain_VB compounds_NNS ,_, inhibitory_NN constants_NNS for_IN
        which_WDT are_VBP as_RB much_JJ as_IN 70_CD -_: fold_VB lower_JJR than_IN natural_JJ substrates_NNS ._.
        Key_JJ features_NNS of_IN the_DT best_JJS candidate_NN agonist_NN compound_NN 
        6_CD b_SYM and_CC candidate_NN antagonist_NN compound_NN 
        12_CD b_SYM are_VBP conservation_NN of_IN the_DT length_NN of_IN
        the_DT polyphosphate_NN replacement_NN ,_, use_NN of_IN 5_CD '_POS -_: 
        O_NNP -_: phosphorothioadenosyl_NN residues_NNS ,_, no_DT
        replacement_NN for_IN oxygen_NN at_IN the_DT location_NN of_IN the_DT α-β_JJ bridging_VBG
        oxygen_NN ,_, and_CC replacement_NN of_IN carbon_NN for_IN the_DT β_NN phosphorus_JJ ._.
        Compound_NN 
        12_CD b_SYM contains_VBZ additional_JJ negatively_RB
        charged_VBN substituents_NNS that_WDT may_MD facilitate_VB Fhit_NNP inhibition_NN [_NN
        15_CD ]_NN while_IN rendering_VBG the_DT compound_NN antagonistic_JJ to_TO Fhit_NNP
        function_NN in_IN the_DT cell_NN ._. Covalent_NNP structures_NNS of_IN AppppA_NNP (_( 
        1_LS )_) and_CC compounds_NNS 
        6_CD b_SYM and_CC 
        12_CD b_SYM are_VBP provided_VBN in_IN Figure_NN 1_CD ._.
      
      
        Results_NNS and_CC Discussion_NNP
        A_DT series_NN of_IN compounds_NNS 
        2_CD -_: 6_CD were_VBD synthesized_JJ and_CC evaluated_VBN for_IN
        Fhit_NNP inhibition_NN that_DT link_NN two_CD 5_CD '_POS -_: 
        O_NNP -_: phosphorothioadenosyl_NN or_CC AMP_NNP
        groups_NNS with_IN five_CD reagents_NNS ranging_VBG in_IN size_NN from_IN ethylene_NN
        glycol_NN to_TO 
        meso_NN -_: erythritol_NN ._. Sodium_NNP salts_NNS of_IN
        each_DT compound_NN were_VBD titrated_JJ into_IN assays_NNS of_IN purified_JJ Fhit_NNP [_NN
        16_CD ]_NN with_IN 1_CD ._. 8_CD μM_NN fluorescent_NN substrate_NN ,_,
        Appp-_NNP S-_NNP (_( 4_CD -_: 4_CD -_: difluoro-_NN 5_CD ,_, 7_CD -_: dimethyl-_NN 4_CD -_: bora-_NN 3_CD a_DT ,_, 4_CD a-diaza-s-indacine-_JJ 3_CD -_: yl_NN )_) methylaminoacetyl_NN
        (_( ApppBODIPY_NNP )_) [_NN 10_CD ]_NN ,_, and_CC competitive_JJ 
        K_NNP 
        i_NNP values_NNS were_VBD obtained_VBN by_IN calculating_VBG
        the_DT inhibitor_NN concentration-dependence_JJ in_IN reduction_NN of_IN 
        k_NN 
        cat_NN /_NN 
        K_NNP 
        m_NN (_( apparent_JJ )_) for_IN substrate_NN hydrolysis_NNS [_NN
        10_CD ]_NN ._. As_IN shown_VBN in_IN Table_NNP 1_CD ,_, inhibitors_NNS 
        2_CD b_SYM and_CC 
        3_CD b_SYM with_IN two-carbon_JJ diol_NN linkers_NNS were_VBD
        either_CC only_RB as_RB inhibitory_NN as_IN the_DT natural_JJ substrate_NN 1_CD or_CC
        substantially_RB less_RBR so_RB ._. Inhibitor_NNP 
        4_CD b_SYM with_IN a_DT four-carbon_JJ linker_NN was_VBD as_RB
        ineffective_JJ as_IN 
        3_CD b_SYM ._. Inhibitors_NNP 
        5_CD a_DT and_NN 
        6_CD a_DT that_DT substitute_NN a_DT central_JJ CH_NNP 
        2_CD -_: PO_NNP 
        2_CD -_: CH_NNP 
        2_CD or_CC CH_NNP 
        2_CD -_: CH_NNP (_( OH_NNP )_) -_: CH_NNP 
        2_CD for_IN the_DT PO_NNP 
        2_CD -_: O-PO_NNP 
        2_CD of_IN 
        1_CD were_VBD as_RB inhibitory_NN as_IN 
        1_CD is_VBZ a_DT good_JJ substrate_NN ._. The_DT
        phosphorothioate_NN analogs_NNS ,_, 
        5_CD b_SYM and_CC 
        6_CD b_SYM ,_, bound_VBN approximately_RB 10_CD and_CC 75_CD times_NNS
        better_JJR to_TO Fhit_NNP than_IN 
        1_CD ._. Thus_RB ,_, conservation_NN of_IN bond-lengths_JJ
        between_IN adenylate_NN moieties_NNS of_IN 
        1_CD ,_, 
        5_CD and_CC 
        6_CD is_VBZ conducive_JJ to_TO binding_JJ Fhit_NNP ._.
        Because_IN phosphorothioate_NN analogs_NNS of_IN 
        5_CD and_CC 
        6_CD were_VBD better_JJR inhibitors_NNS than_IN the_DT
        corresponding_JJ phosphates_NNS ,_, phosphorodithioate_NN analog_NN 
        6_CD c_SYM was_VBD prepared_VBN together_RB with_IN five_CD
        additional_JJ compounds_NNS as_IN phosphates_NNS and_CC phosphorothioates_NNS ._.
        Phosphorodithioate_NNP 
        6_CD c_SYM was_VBD a_DT less_RBR effective_JJ inhibitor_NN (_( 
        K_NNP 
        i_NNP =_SYM 8600_CD nM_NN ,_, not_RB shown_VBN in_IN Tables_NNP )_) than_IN
        corresponding_JJ phosphate_NN 
        6_CD a_DT and_NN phosphorothioate_NN 
        6_CD b_SYM and_CC ,_, as_IN demonstrated_VBN in_IN Tables_NNP 1_CD and_CC
        2_CD ,_, the_DT phosphorothioate_NN congener_NN of_IN every_DT compound_NN made_VBN as_IN
        a_DT phosphate_NN and_CC a_DT phosphorothioate_NN had_VBD a_DT lower_JJR 
        K_NNP 
        i_NNP value_NN ._. The_DT contribution_NN of_IN particular_JJ
        P-_NNP chiral_NN phosphorothioate_NN stereoisomers_NNS to_TO inhibition_NN has_VBZ
        not_RB been_VBN examined_VBN ._. When_WRB diadenosine_NN 5_CD '_POS ,_, 5_CD "_'' '_POS -_: (_( 
        P_NN 1_CD ,_, 
        P_NN 2_CD -_: methylene-_NN 
        P_NN 3_CD -_: thio_NN )_) -_: 
        P_NN 1_CD ,_, 
        P_NN 3_CD -_: triphosphate_NN [_NN 17_CD ]_NN was_VBD
        crystallized_JJ with_IN wild-type_JJ and_CC mutant_JJ Fhit_NNP ,_, the_DT
        α-phosphorothioate_JJ group_NN was_VBD found_VBN in_IN the_DT mutant_JJ but_CC not_RB
        wild-type_JJ active_JJ site_NN ,_, suggesting_VBG that_IN α-phosphorothioate_JJ
        inhibitors_NNS may_MD be_VB slow_JJ substrates_NNS [_NN 12_CD ]_NN ._. Similarly_RB ,_, Frey_NNP
        and_CC co-workers_NNS found_VBD that_IN Fhit_NNP slowly_RB cleaves_NNS both_DT R_NN 
        p_NN and_CC S_NNP 
        p_NN stereoisomers_NNS of_IN γ-_NN (_( 
        m_NN -_: nitrobenzyl_NN )_) -_: adenosine_NN 5_CD '_POS -_: 
        O_NNP -_: (_( l-thiotriphosphate_JJ )_) with_IN modest_JJ
        and_CC similar_JJ beneficial_JJ effects_NNS on_IN 
        K_NNP 
        m_NN as_IN compared_VBN to_TO the_DT corresponding_JJ
        phosphate_NN [_NN 13_CD ]_NN ._.
        Given_VBN the_DT inhibitor_NN activity_NN of_IN 
        6_CD b_SYM ,_, the_DT contribution_NN of_IN the_DT oxygen_NN in_IN
        the_DT position_NN of_IN the_DT α-β_JJ bridging_VBG oxygen_NN of_IN 
        1_CD was_VBD examined_VBN ._. As_IN can_MD be_VB seen_VBN in_IN Table_NNP
        2_CD ,_, comparison_NN of_IN 
        9_CD b_SYM with_IN 
        10_CD b_SYM and_CC 
        11_CD b_SYM and_CC of_IN 
        15_CD b_SYM with_IN 
        16_CD b_SYM indicated_VBD that_DT imido_NN or_CC sulfur_NN
        substitutions_NNS for_IN oxygen_NN reduce_VB enzyme_NN inhibition_NN by_IN an_DT
        order_NN of_IN magnitude_NN ._. Derivatives_NNP of_IN 
        6_CD b_SYM with_IN one_CD or_CC two_CD additional_JJ
        functionalities_NNS on_IN the_DT central_JJ carbon_NN were_VBD characterized_VBN ._.
        Analysis_NNP of_IN 
        9_CD b_SYM indicated_VBD that_DT loss_NN of_IN the_DT polar_JJ
        hydroxyl_NN group_NN reduces_VBZ inhibitory_NN activity_NN and_CC analysis_NN of_IN 
        7_CD b_SYM and_CC 
        8_CD b_SYM indicated_VBD that_IN nearly_RB isosteric_JJ
        groups_NNS that_WDT are_VBP nonisoelectronic_JJ are_VBP not_RB tolerated_JJ ._. The_DT
        magnitude_NN of_IN these_DT effects_NNS was_VBD surprising_JJ and_CC may_MD be_VB
        related_VBN to_TO altered_VBN conformations_NNS upon_IN manganese_NN
        coordination_NN ._. Earlier_RBR ,_, Blackburn_NNP and_CC co-workers_NNS made_VBN
        "_'' supercharged_JJ "_'' methane-trisphosphonic_JJ acid_NN AppppA_NNP analogs_NNS
        containing_VBG a_DT central_JJ carbon_NN from_IN which_WDT three_CD adenylate_NN or_CC
        phosphate_NN moieties_NNS are_VBP bonded_VBN [_NN 15_CD ]_NN ._. In_IN work_NN presented_VBN
        here_RB ,_, tripodal_NN inhibitors_NNS 
        15_CD a_DT and_NN 
        17_CD a_DT showed_VBD ,_, respectively_RB ,_, micromolar_NN
        and_CC submicromolar_NN efficacies_NNS while_IN the_DT phosphorothioate_NN
        counterparts_NNS 
        15_CD b_SYM and_CC 
        17_CD b_SYM showed_VBD 100_CD nM_NN efficacy_NN ._.
        Derivatives_NNP of_IN pentaerythritol_NN ,_, tetrapodal_NN compounds_NNS 
        12_CD ,_, 13_CD and_CC 
        14_CD ,_, were_VBD also_RB evaluated_VBN for_IN Fhit_NNP
        inhibition_NN ._. While_IN compound_NN 
        14_CD b_SYM ,_, containing_VBG two_CD phosphorothioylated_JJ
        branches_NNS without_IN adenosine_NN ,_, was_VBD barely_RB a_DT submicromolar_NN
        inhibitor_NN ,_, compounds_NNS 
        12_CD b_SYM and_CC 
        13_CD b_SYM ,_, which_WDT contain_VBP respectively_RB three_CD
        and_CC four_CD CH_NNP 
        2_CD -_: phosphorothioadenosyl_NN groups_NNS bonded_VBN
        to_TO the_DT central_JJ carbon_NN were_VBD 40_CD nM_NN and_CC 65_CD nM_NN inhibitors_NNS ._.
        Thus_RB ,_, while_IN the_DT simplest_JJS compound_NN 
        6_CD b_SYM was_VBD initially_RB rendered_VBN less_JJR
        inhibitory_NN by_IN modification_NN because_IN its_PRP$ central_JJ hydroxyl_NN was_VBD
        important_JJ for_IN inhibition_NN ,_, addition_NN of_IN one_CD or_CC two_CD CH_NNP 
        2_CD -_: phosphorothioadenosyl_NN groups_NNS restored_VBD
        inhibition_NN ._. We_PRP presume_NN that_IN compounds_NNS 
        6_CD b_SYM ,_, 
        12_CD b_SYM and_CC 
        13_CD b_SYM with_IN 2_CD ,_, 3_CD or_CC 4_CD identical_JJ CH_NNP 
        2_CD -_: phosphorothioadenosyl_NN groups_NNS can_MD
        present_VB a_DT manganese_NN bound_VBN 
        6_CD b_SYM -_: like_IN complex_JJ to_TO Fhit_NNP in_IN a_DT similar_JJ
        manner_NN ._. On_IN the_DT basis_NN that_IN Fhit_NNP binds_NNS diadenosine_NN
        polyphosphates_NNS with_IN one_CD AMP_NNP group_NN buried_VBN and_CC the_DT other_JJ
        adenosine_NN solvent-exposed_JJ in_IN a_DT specific_JJ conformation_NN [_NN 12_CD ]_NN
        ,_, effective_JJ tri_NN and_CC tetrapodal_NN inhibitors_NNS such_JJ as_IN 
        12_CD b_SYM ,_, 13_CD b_SYM and_CC HC_NNP (_( ADP_NNP )_) 
        3_CD [_NN 15_CD ]_NN may_MD exist_VB in_IN solution_NN
        predominantly_RB in_IN a_DT conformation_NN that_WDT resembles_VBZ Fhit-bound_NNP
        AppppA_NNP ._.
        On_IN the_DT basis_NN of_IN observations_NNS [_NN 12_CD 13_CD ]_NN discussed_VBN above_IN ,_,
        one_PRP would_MD expect_VB AppppA_NNP with_IN two_CD phosphorothioadenosyl_NN
        substituents_NNS to_TO be_VB a_DT slow_JJ substrate_NN with_IN a_DT relatively_RB low_JJ 
        K_NNP 
        m_NN ._. However_RB ,_, carbon_NN in_IN place_NN of_IN the_DT β_NN
        phosphorus_JJ (_( for_IN example_NN in_IN 
        6_CD b_SYM )_) would_MD make_VB the_DT leaving_VBG group_NN the_DT
        alkoxide_NN -_: OCH_NNP 
        2_CD -_: CH_NNP (_( OH_NNP )_) -_: CH_NNP 
        2_CD O-_NNP phosphorothioadenosyl_NN rather_RB than_IN
        α-thio_JJ ATP_NNP ._. Presumably_RB ,_, because_IN normal_JJ Fhit_NNP products_NNS are_VBP
        mononucleotides_NNS with_IN low_JJ p_NN 
        K_NNP 
        a_DT values_NNS ,_, the_DT enzyme_NN does_VBZ not_RB have_VB a_DT
        group_NN to_TO protonate_NN an_DT alkoxide_NN leaving_VBG group_NN and_CC thus_RB
        substitution_NN of_IN carbon_NN for_IN the_DT β_NN phosphorus_JJ turns_VBZ a_DT
        substrate_NN into_IN an_DT inhibitor_NN ._.
      
      
        Conclusions_NNP
        Tumor_NNP suppression_NN by_IN Fhit_NNP is_VBZ not_RB destroyed_VBN by_IN mutation_NN
        of_IN the_DT nucleophilic_JJ His_PRP$ 96_CD to_TO Asn_NNP ,_, a_DT mutation_NN that_WDT
        specifically_RB reduces_VBZ 
        k_NN 
        cat_NN [_NN 2_CD 12_CD ]_NN ._. Thus_RB ,_, evidence_NN suggests_VBZ
        that_IN the_DT proapoptotic_JJ function_NN of_IN Fhit_NNP depends_VBZ on_IN formation_NN
        of_IN an_DT E-S_NNP complex_NN ._. If_IN the_DT substrate-dependent_JJ signaling_VBG
        model_NN is_VBZ correct_JJ ,_, then_RB compound_NN 
        6_CD b_SYM ,_, as_IN a_DT nearly_RB isosteric_JJ AppppA_NNP analog_NN
        with_IN a_DT low_JJ 
        K_NNP 
        i_NNP ,_, may_MD promote_VB Fhit_NNP signaling_VBG in_IN Fhit_NNP +_NN
        cells_NNS ._. Compound_NN 
        12_CD b_SYM ,_, which_WDT one_PRP would_MD expect_VB to_TO bind_NN
        Fhit_NNP with_IN bulky_JJ phosphorothioate_NN and_CC phosphorothioadenosyl_NN
        groups_NNS interfering_VBG with_IN putative_JJ effector_NN binding_JJ ,_, may_MD
        consequently_RB prove_VB to_TO be_VB antagonistic_JJ to_TO Fhit_NNP function_NN ._.
        Ongoing_NNP 
        in_IN vitro_NN studies_NNS aim_VBP to_TO evaluate_VB the_DT
        stereochemistry_NN of_IN phosphorothioyl_NN binding_JJ to_TO Fhit_NNP while_IN 
        in_IN vivo_NN studies_NNS test_VBP the_DT effects_NNS of_IN
        these_DT compounds_NNS on_IN programmed_VBN cell_NN death_NN ._. Phosphorothioate_NNP
        analogs_NNS 
        6_CD b_SYM and_CC 
        12_CD b_SYM that_WDT preserve_VB the_DT α-β_JJ bridging_VBG
        oxygen_NN but_CC substitute_NN carbon_NN for_IN the_DT β_NN phosphorus_JJ ,_,
        achieving_VBG 65_CD to_TO 75_CD -_: fold_VB binding_JJ advantages_NNS over_IN AppppA_NNP ,_, are_VBP
        expected_VBN to_TO be_VB critical_JJ for_IN cell_NN biological_JJ
        characterization_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Synthesis_NNP and_CC Characterization_NNP
          
            Synthesis_NNP of_IN
            5_CD '_POS -_: O-_NNP (_( 2_CD -_: thiono-_NN 1_CD ,_, 3_CD ,_, 2_CD -_: oxathiaphospholane_NN )_) -_: N_NNP 6_CD ,_, N_NNP 6_CD ,_, O_NNP 2_CD '_POS ,_, O_NNP
            3_CD '_POS -_: tetrabenzoyladenosine_NN (_( 18_CD )_)
            N_NNP 6_CD ,_, N_NNP 6_CD ,_, O_NNP 2_CD '_POS ,_, O_NNP 3_CD '_POS -_: tetrabenzoyladenosine_NN (_( 1_CD mmol_NN )_) was_VBD
            reacted_VBN with_IN 2_CD -_: chloro-_NN 1_CD ,_, 3_CD ,_, 2_CD -_: oxathiaphospholane_NN (_( 1_CD ._. 1_LS
            mmol_NN )_) in_IN pyridine_NN solution_NN (_( 3_CD ml_NN )_) in_IN the_DT presence_NN of_IN
            elemental_NN sulfur_NN (_( 5_CD mmol_NN )_) ._. After_IN stirring_VBG for_IN 12_CD h_NN at_IN
            room_NN temperature_NN ,_, the_DT solvent_JJ was_VBD removed_VBN under_IN reduced_VBN
            pressure_NN and_CC the_DT crude_NN product_NN was_VBD purified_JJ by_IN silica_NN
            gel_NN column_NN chromatography_NN using_VBG chloroform_NN :_: hexane_NN (_( 8_CD :_: 2_LS )_)
            as_IN an_DT eluent_NN to_TO provide_VB 
            18_CD in_IN 72_CD %_NN yield_NN [_NN 31_CD P_NN NMR_NNP 105_CD ._. 2_LS ppm_NN
            (_( d_SYM )_) ,_, FAB-MS_NNP (_( M-_NNP 1_LS )_) m_NN /_NN z_SYM 820_CD ]_NN ._.
          
          
            Synthesis_NNP of_IN
            5_CD '_POS -_: O-_NNP (_( 2_CD -_: thiono-_NN 1_CD ,_, 3_CD ,_, 2_CD -_: dithiaphospholane_NN )_) -_: N_NNP 6_CD ,_, N_NNP 6_CD ,_, O_NNP 2_CD '_POS ,_, O_NNP
            3_CD '_POS -_: tetrabenzoyladenosine_NN (_( 19_CD )_)
            N_NNP 6_CD ,_, N_NNP 6_CD ,_, O_NNP 2_CD '_POS ,_, O_NNP 3_CD '_POS -_: tetrabenzoyladenosine_NN (_( 1_CD mmol_NN )_) was_VBD
            reacted_VBN with_IN 2_CD -_: chloro-_NN 1_CD ,_, 3_CD ,_, 2_CD -_: dithiaphospholane_NN [_NN 18_CD ]_NN in_IN
            pyridine_NN solution_NN (_( 3_CD ml_NN )_) in_IN the_DT presence_NN of_IN elemental_NN
            sulfur_NN (_( 5_CD mmol_NN )_) ._. After_IN stirring_VBG for_IN 12_CD h_NN at_IN room_NN
            temperature_NN ,_, the_DT solvent_JJ was_VBD removed_VBN under_IN reduced_VBN
            pressure_NN and_CC the_DT crude_NN product_NN was_VBD purified_JJ by_IN silica_NN
            gel_NN column_NN chromatography_NN using_VBG chloroform_NN :_: hexane_NN (_( 8_CD :_: 2_LS )_)
            as_IN an_DT eluent_NN to_TO give_VB 
            19_CD in_IN 68_CD %_NN yield_NN [_NN 31_CD P_NN NMR_NNP 115_CD ._. 2_LS
            ppm_NN ,_, FAB-MS_NNP (_( M-_NNP 1_LS )_) m_NN /_NN z_SYM 836_CD ]_NN ._.
          
          
            Synthesis_NNP of_IN tetra-oxathiaphosphothioylated_JJ
            erythritol_NN (_( 20_CD )_) or_CC tri-oxathiaphosphothioylated_JJ
            glycerol_NN (_( 21_CD )_)
            2_LS -_: chloro-_NN 1_CD ,_, 3_CD ,_, 2_CD -_: oxathiaphospholane_NN (_( 8_CD mmol_NN )_) was_VBD added_VBN
            to_TO a_DT suspension_NN of_IN elemental_NN sulfur_NN (_( 10_CD mmol_NN )_) in_IN
            pyridine_NN (_( 10_CD ml_NN )_) ._. A_DT solution_NN of_IN glycerol_NN (_( 1_CD ._. 5_LS mmol_NN )_) or_CC
            erythritol_NN (_( 1_CD ._. 5_LS mmol_NN )_) in_IN pyridine_NN (_( 1_CD ml_NN )_) was_VBD then_RB
            introduced_VBN to_TO the_DT reaction_NN mixture_NN and_CC stirred_VBD for_IN 12_CD h_NN
            at_IN room_NN temperature_NN ._. Crude_JJ products_NNS were_VBD purified_JJ by_IN
            silica_NN gel_NN column_NN chromatography_NN using_VBG
            chloroform_NN :_: hexane_NN (_( 7_CD :_: 3_LS )_) to_TO give_VB 
            22_CD in_IN 77_CD %_NN yield_NN [_NN 31_CD P_NN NMR_NNP 105_CD ._. 6_CD ppm_NN
            (_( m_NN )_) ,_, FAB-MS_NNP (_( M-_NNP 1_LS )_) m_NN /_NN z_SYM 505_CD ]_NN or_CC 
            21_CD in_IN 60_CD %_NN yield_NN [_NN 31_CD P_NN NMR_NNP 105_CD ._. 1_LS ppm_NN
            (_( m_NN )_) ,_, FAB-MS_NNP (_( M-_NNP 1_LS )_) m_NN /_NN z_SYM 687_CD ]_NN ,_, respectively_RB ._.
          
          
            Condensation_NNP of_IN oxathiaphospholane_NN derivatives_NNS
            with_IN polyols_NNS
            A_DT mixture_NN of_IN 1_CD ,_, 8_CD -_: diazabicyclo_NN (_( 5_CD ,_, 4_CD ,_, 0_CD )_) undec-_NN 7_CD -_: ene_NN
            with_IN the_DT corresponding_JJ polyol_NN (_( one_CD equivalent_NN of_IN
            1_CD ,_, 8_CD -_: diazabicyclo_NN (_( 5_CD ,_, 4_CD ,_, 0_CD )_) undec-_NN 7_CD -_: ene_NN per_IN -_: OH_NNP function_NN )_)
            in_IN 1_CD ml_NN acetonitrile_NN solution_NN was_VBD added_VBN to_TO the_DT solution_NN
            of_IN one_CD molar_NN equivalent_NN of_IN oxathiaphospholane_NN
            derivative_JJ (_( 
            18_CD ,_, 19_CD ,_, 20_CD or_CC 
            21_CD )_) dissolved_VBN in_IN dry_JJ acetonitrile_NN
            (_( 5_CD ml_NN )_) ._. The_DT reaction_NN mixtures_NNS were_VBD stirred_VBD at_IN room_NN
            temperature_NN for_IN 4_CD hours_NNS and_CC then_RB solvent_JJ was_VBD removed_VBN
            under_IN reduced_VBN pressure_NN ._. Purified_NNP compounds_NNS were_VBD
            obtained_VBN by_IN Sephadex_NNP A-_NNP 25_CD ion-exchange_JJ chromatography_NN
            using_VBG a_DT linear_JJ gradient_NN of_IN ammonium_NN bicarbonate_NN buffer_NN
            (_( pH_NN 7_CD ._. 5_LS )_) as_IN eluent_NN ,_, and_CC their_PRP$ physicochemical_JJ
            characteristics_NNS are_VBP given_VBN in_IN Table_NNP 3_CD ._.
          
        
        
          Enzyme_NNP inhibition_NN assays_NNS
          Inhibitors_NNP ,_, at_IN approximately_RB 
          4_CD ,_, 2_CD ,_, 1_CD ,_, 0_CD ._. 5_CD and_CC 0_CD ._. 25_CD times_NNS 
          K_NNP 
          i_NNP value_NN ,_, were_VBD added_VBN to_TO assays_NNS of_IN Fhit_NNP
          with_IN ApppBODIPY_NNP [_NN 10_CD ]_NN ._. 
          K_NNP 
          i_NNP values_NNS were_VBD obtained_VBN by_IN calculating_VBG
          the_DT inhibitor_NN concentration-dependence_JJ in_IN reduction_NN of_IN 
          k_NN 
          cat_NN /_NN 
          K_NNP 
          m_NN (_( apparent_JJ )_) as_IN earlier_RBR described_VBD [_NN 10_CD
          ]_NN ._.
        
      
    
  
